January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC
Dec 19, 2024, 12:55

Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC

Arndt Vogel, Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School, shared a recent article by Mohammad Saeid Rezaee-Zavareh on X:

“Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis just published today in Journal of Hepatology.

Title: Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis

Authors: Mohammad Saeid Rezaee-Zavareh, Yee Hui Yeo, Tielong Wang, Zhiyong Guo, Parissa Tabrizian, Stephen C. Ward, Fatma Barakat, Tarek I. Hassanein, Shravan Dave, Veeral Ajmera, Sherrie Bhoori, Vincenzo Mazzaferro, David M.H. Chascsa, Margaret C. Liu, Elizabeth S. Aby, John R. Lake, Miguel Sogbe, Bruno Sangro, Maen Abdelrahim, Abdullah Esmail, Andreas Schmiderer, Yasmina Chouik, Mark Rudolph, Davendra Sohal, Heloise Giudicelli, Manon Allaire, Mehmet Akce, Jessica Guadagno, Clara Y. Tow, Hatef Massoumi, Paolo De Simone, Elise Kang, Robyn D. Gartrell, Mercedes Martinez, Ricardo Paz-Fumagalli, Beau B. Toskich, Nguyen H. Tran, Gabriela Azevedo Solino, Dra Mariana Poltronieri Pacheco, Richard S. Kalman, Vatche G. Agopian, Neil Mehta, Neehar D. Parikh, Amit G. Singal and Ju Dong Yang

Arndt Vogel

 

Arndt Vogel, MD, is a Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School. Leading the GI-Cancer Center and the Center for Personalized Medicine, his research focuses on translational and clinical studies in gastrointestinal cancer. He’s actively engaged in various societies including ESMO, ASCO, and EASL. Additionally, he chairs the Hepatobiliary Cancer Study Group of the AIO, contributing significantly to clinical oncology in Germany. Within ESMO, he serves on the Guidelines Steering Committee.

More posts featuring Arndt Vogel.